For adults and children with hemophilia B
Zero median annualized spontaneous bleeding rate in adults when dosed at 7 or 14 days in phase III pivotal trials
EXPLORE IDELVION*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month while not requiring dose adjustments or experiencing spontaneous bleeding.
†The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg.
So your eligible patients can see if it’s right for them
Recommended for mobile devices
CSL Behring is committed to providing treatments and support services that make a meaningful difference in the lives of people with bleeding disorders.
Resources are available to help your eligible patients get the treatment they need for hemophilia B, including:
References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735.